COMMON STOCK PURCHASE WARRANT CITIUS PHARMACEUTICALS, INC.Common Stock Purchase Warrant • February 19th, 2020 • Citius Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ________________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on August 19, 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Citius Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to _______________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
WARRANT EXERCISE AGREEMENTWarrant Exercise Agreement • February 19th, 2020 • Citius Pharmaceuticals, Inc. • Pharmaceutical preparations
This Warrant Exercise Agreement (this “Agreement”), dated as of February 14, 2020, is by and between Citius Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and the undersigned holder (each, a “Holder” and, collectively, the “Holders”) of warrants to purchase shares of common stock of the Company, par value $0.001 per share (the “Common Stock”), at an exercise price of $0.77 per share, issued by the Company on September 27, 2019 in connection with its underwritten public Offering (the “September 2019 Warrants”) and warrants to purchase Common Stock, at an exercise price of $2.86 per share, issued by the Company on March 29, 2018 (the “March 2019 Warrants”, and together with the September 2019 Warrants, the “Original Warrants”).
